hotspot -WSS

hotspot

author：focus 2025-09-06 04:12:42 - browse：677

Tortoise and hare — Medical devices have historically been seen as having faster paths to market than their pharmacological counterparts. The growing requirement for cost-effectiveness trials may be slowing them down. Jonathan Elderfield/AP

When a colleague and I started our medical device company in 2009, we were in our second year at Harvard Medical School. Some classmates joked that they would still be in residency by the time we had moved on to our next big idea. We knew better — we expected it to be a long haul. Eight years into our journey, thousands of individuals have used our product in countries where it has been approved. But we have yet to gain approval in the U.S. — a long and expensive process.

In 2016, the United States Food and Drug Administration approved 22 new drugs, down from 45 approvals in 2015. The decline in drug discovery has been attributed to a variety of factors that include ballooning research and development expenses (the cost to develop a new drug is now estimated to be more than $2.5 billion), high rates of failure (a whopping 90 percent of Phase 1 candidates never make it to launch), and the complexity of human biology, which can thwart even the most promising candidates.

Medical devices have historically been viewed as having faster and lower-cost paths to market than their pharmacological counterparts: the average cost to develop high-risk, novel medical devices is estimated to be $94 million. After all, device engineers can leverage lower-cost animal models further into development than their pharmaceutical colleagues, the human clinical trials necessary for FDA approval are often smaller in scale, and, in some cases, expenses can be defrayed by revenue generated outside the United States in markets with faster regulatory pathways.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Advances in CAR

entertainment

WSS

Stem cell treatment guidelines are released by FDA

Snackable artificial intelligence, expert AI, and the pharma industry

How to protect coverage of PrEP

Woman found dead after suspected bear encounter near Yellowstone, wildlife officials say

Trump surgeon general acknowledges mistakes during Covid

Sophia Smith scores twice for US in in 3

hotspot

hotspot

leisure time

How to save PrEP access — and even expand it

How to protect coverage of PrEP

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

How a key Senate committee is planning to regulate PBMs

What does generative AI mean for health care? We asked experts

A new House health package & hospitals’ new site

In Memoriam: Notable people who died in 2023

Amazon on where the company's health care bets are headed next

Psychedelics group wrestles with new pharma identity

Crinetics acromegaly drug succeeds in late

entertainment

FDA approves first blood sugar monitor without finger pricks

Medicaid rebukes states for mistakenly disenrolling children

A new House health package & hospitals’ new site

Charges dismissed against white woman who spat on Black woman during protests in Connecticut

Malaysia cuts short music fest after British band slams anti

Clinic falsely told dozens they had Alzheimer's, suits say

hotspot

entertainment

focus

explore